FDA Orange Book
Is there a generic for Bonjesta?
Bonjesta contains doxylamine and pyridoxine. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
No. The Orange Book lists no active FDA-approved generic (ANDA) for Bonjesta (doxylamine and pyridoxine). The Orange Book shows its last listed patent expires February 18, 2033.
Run it in Rivvi
Map Bonjesta and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Bonjesta products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| tablet, extended release, oral | 20MG;20MG | Marketed (Rx) | None | 0 | None |
NDA 209661, held by DUCHESNAY INC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Bonjesta patents
| Patent | Expires | Covers | Use code | NDA |
|---|---|---|---|---|
| 9937132 | February 18, 2033 | Drug product | U-1382 | 209661 |
| 9375404 | February 18, 2033 | Drug product | U-1382 | 209661 |
| 9526703 | February 18, 2033 | Drug product | U-1382 | 209661 |
| 9089489 | February 18, 2033 | Drug product | U-1382 | 209661 |
Bonjesta NDC codes
Questions
Is there a generic for Bonjesta?
No. The Orange Book lists no active FDA-approved generic (ANDA) for Bonjesta (doxylamine and pyridoxine). The Orange Book shows its last listed patent expires February 18, 2033.
What is the generic name for Bonjesta?
The active ingredient in Bonjesta is doxylamine and pyridoxine, per the FDA Orange Book.
When does the Bonjesta patent expire?
The last patent listed for Bonjesta in the Orange Book expires February 18, 2033. A listed patent expiry date is not a generic launch date.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.